Proteomic-Based Biosignatures in Breast Cancer Classification and Prediction of Therapeutic Response

Figure 2

Representative proteins differentially expressed by HER2+ and TNBC tumors. (a)–(c): proteins preferentially expressed in TNBC. (d)-(e): proteins preferentially expressed in HER2+ tumors.

(a) ALDH1A1

(b) Galectin-3-binding protein

(c) Complement component 1 inhibitor

(d) Cytokeratin-19

(e) Transketolase

(f) Transferrin